Affimed N.V. (NASDAQ:AFMD) Given Consensus Recommendation of “Hold” by Brokerages
Affimed N.V. (NASDAQ:AFMD) has earned an average recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $5.38.
A number of equities research analysts have weighed in on AFMD shares. Oppenheimer Holdings, Inc. set a $10.00 price target on shares of Affimed N.V. and gave the company a “buy” rating in a report on Saturday, April 15th. Zacks Investment Research raised shares of Affimed N.V. from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a report on Wednesday, April 19th. Jefferies Group LLC upped their price target on shares of Affimed N.V. to $2.50 and gave the company a “hold” rating in a report on Wednesday, April 26th. ValuEngine raised shares of Affimed N.V. from a “strong sell” rating to a “sell” rating in a report on Friday, June 30th. Finally, SunTrust Banks, Inc. started coverage on shares of Affimed N.V. in a report on Thursday, July 13th. They issued a “buy” rating and a $7.00 price target for the company.
A number of hedge funds have recently bought and sold shares of the company. Creative Planning increased its stake in Affimed N.V. by 7.7% in the second quarter. Creative Planning now owns 70,000 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 5,000 shares during the last quarter. Nationwide Fund Advisors increased its stake in Affimed N.V. by 9,542.0% in the first quarter. Nationwide Fund Advisors now owns 484,027 shares of the biopharmaceutical company’s stock valued at $1,113,000 after buying an additional 479,007 shares during the last quarter. Tekla Capital Management LLC increased its stake in Affimed N.V. by 377.7% in the first quarter. Tekla Capital Management LLC now owns 1,405,324 shares of the biopharmaceutical company’s stock valued at $3,232,000 after buying an additional 1,111,111 shares during the last quarter. NEA Management Company LLC bought a new stake in Affimed N.V. during the first quarter valued at about $8,944,000. Finally, Wellington Management Group LLP increased its stake in Affimed N.V. by 30.8% in the first quarter. Wellington Management Group LLP now owns 5,413,291 shares of the biopharmaceutical company’s stock valued at $12,450,000 after buying an additional 1,274,852 shares during the last quarter. Hedge funds and other institutional investors own 42.41% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Affimed N.V. (NASDAQ:AFMD) Given Consensus Recommendation of “Hold” by Brokerages” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/07/affimed-n-v-nasdaqafmd-given-consensus-recommendation-of-hold-by-brokerages.html.
Affimed N.V. (AFMD) opened at 2.10 on Monday. The firm’s 50-day moving average is $2.22 and its 200 day moving average is $2.23. Affimed N.V. has a 12-month low of $1.65 and a 12-month high of $3.25. The stock’s market capitalization is $92.27 million.
Affimed N.V. (NASDAQ:AFMD) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.02. Affimed N.V. had a negative net margin of 978.31% and a negative return on equity of 73.85%. The company had revenue of $0.51 million during the quarter, compared to the consensus estimate of $1.31 million. During the same period in the prior year, the company earned ($0.24) EPS. Affimed N.V.’s revenue was down 75.4% on a year-over-year basis. Equities research analysts anticipate that Affimed N.V. will post ($0.86) earnings per share for the current year.
Affimed N.V. Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.